Summary: Prevencio received a patent for its AI-powered blood test which accurately assesses the risk of obstructive coronary artery disease, outperforming traditional diagnostic methods.

Takeaways:

  1. Patent Achievement: Prevencio’s HART CADhs test, developed using AI technology, has been granted a patent, marking the fourth patent in their portfolio of advanced cardiovascular diagnostics.
  2. Superior Accuracy: In collaboration with Massachusetts General Hospital, the HART CADhs test demonstrated an 86% AUC accuracy, significantly higher than the 52% accuracy of standard-of-care tests.
  3. Healthcare Impact: With cardiovascular disease being a leading cause of death and substantial healthcare costs, Prevencio’s HART CADhs and HART CVE tests aim to improve patient outcomes and reduce costs, addressing a critical need in the healthcare system.

Prevencio, a leader in AI-powered blood tests for cardiovascular diagnostics, announced that the United States Patent and Trademark Office has issued a patent for its blood test, HART CADhs, which assesses a patient’s risk of obstructive coronary artery disease, also referred to as obstructive heart disease. 

The company utilized its Artificial Intelligence (AI)-driven HART platform and expertise in cardiac blood tests to develop HART CADhs.

“Prevencio is pleased with the advancement of our patent portfolio, which is crucial for maintaining our competitive advantage,” said Rhonda Rhyne, president and CEO of Prevencio. “This is the fourth patent issued for our novel AI-driven, multiple protein blood tests. We have several more patents pending.”

Heart Disease Blood Test Developed with Help from AI

In research conducted with Massachusetts General Hospital, HART CADhs demonstrated an 86% AUC accuracy, outperforming standard-of-care tests such as exercise, echocardiography, and nuclear stress tests which collectively had an accuracy of 52% AUC.

Cardiovascular disease is the leading cause of death in the U.S. and globally. According to the American Heart Association (AHA), the U.S. spends approximately $318 billion annually on cardiovascular disease and stroke, or approximately 10% of the $3.2 trillion spent on total healthcare. By 2030, AHA projects that 45% of the U.S. adult population will have cardiovascular disease, with healthcare-related expenditures exceeding $1 trillion.

“Given the cost, complexity, and pervasiveness of cardiovascular disease, our highly accurate and accessible HART blood tests are well-positioned to improve patient outcomes while reducing costs,” says Rhyne.

In addition to the HART CADhs test for diagnosing heart artery obstruction, Prevencio offers a second multi-protein blood test, HART CVE, which assesses one-year risk of a heart attack, stroke or cardiovascular death. HART CADhs and HART CVE tests are currently available to medical professionals for patient use.

Further reading: How New Machine Learning Models Can Help Diagnose Women’s Heart Disease